Solid Biosciences, Inc. Securities Litigation

If you purchased a significant amount of shares of Solid Biosciences Inc. (NASDAQ: SLDB), you have certain options. Investors should register for updates.

 

Lawsuit Overview

Defendant:Solid Biosciences Inc.
Date Filed:March 27th, 2018
Sector:Health Care
Industry:Biotechnology: Biological Products (No Diagnostic Substances)
Class Start Date:January 25th, 2018
Class End Date:March 14th, 2018

According to the Complaint, Solid Biosciences, Inc. purportedly seeks to cure Duchenne muscular dystrophy, or DMD. The Company's lead product candidate, SGT-001, is a gene transfer under development to restore functional dystrophin protein expression in patients' muscles. The Company's therapy uses adeno-associated virus (AAV) to deliver the transgene into the patient.

The Complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose: (1) that Solid Biosciences' lead drug candidate SGT-001 had a high likelihood of causing adverse events in patients; (2) that Solid Biosciences misled investors regarding the toxicity of SGT-001; and (3) that, as a result of the foregoing, Defendants' statements in the Registration Statement regarding Solid Biosciences' business, operations, and prospects, were materially false and/or misleading.

Sign up for free to create a personalized portfolio with tracking and e-mail alerts for Solid Biosciences Inc.

 
First Identified Complaint

James Watkins, et al. v. Solid Biosciences, Inc., et al.

Date Filed:March 27th, 2018
Class Period Start:January 25th, 2018
Class Period End:March 14th, 2018
First Identified Complaint Filings
#Document TitleFiling Date